March 29, 2021
Article
The analysis found that more than twice as many women who received olaparib were still alive 5 years after the beginning of the study with no progression of their cancer.
March 25, 2021
DKN-01 is a humanized monoclonal antibody that binds to and blocks the activity of the Dickkopf-1 (DKK1) protein, which activates the innate immune system in the tumor microenvironment and anti-tumor activity.
March 24, 2021
Results from the phase 3 KEYNOTE-775/study 309 trial found that Keytruda plus Lenvima reduced risk of death by 38%, with a median overall survival of 18.3 months
March 23, 2021
When analyzing the odds of death or hospitalization due to COVID-19, the researchers found that use of cytotoxic chemotherapy did not predict increased risk for either.
The company received Fast Track designation from the FDA for GEN-1, a DNA-mediated interleukin-12 (IL-12) immunotherapy.
The IGCS Mentorship and Training Program seeks to provide training and education to regions without formal training programs in gynecologic oncology.
March 22, 2021
According to study results presented at the SGO meeting, biopsies showed no signs of cancer or precancer in two-thirds of 165 women with stage I endometrial cancer or atypical endometrial hyperplasia, 6 months after insertion of the hormonal IUD.
June 24, 2020
The objective of the study was to examine a large clinical dataset of LGSC through the Ovarian Cancer Association Consortium, with the primary goal of identifying factors that affect survival.
June 23, 2020
A study presented at the Society of Gynecologic Oncology 2020 Annual Meeting on Women’s Cancer showed menstrual cups may provide a novel, less invasive, and more comfortable approach to the diagnosis of endometrial cancer.
June 22, 2020
With new and varying options for maintenance therapy in patients with ovarian cancer, patients may express a preference when discussing potential maintenance treatments and their adverse effects.
